Association Between E-FABP Levels, Disease Severity, and Metabolic Parameters in Hidradenitis Suppurativa

Mehmet Ali Seyirci; Selma Korkmaz; Havva Hilal Ayvaz Çelik; Fevziye Burcu Şirin; Mehmet  Bedir; Hikmet  Orhan

doi:10.5826/dpc.1601a6217

Association Between E-FABP Levels, Disease Severity, and Metabolic Parameters in Hidradenitis Suppurativa

Authors

Mehmet Ali Seyirci Isparta City Hospital/Turkey
Selma Korkmaz Suleyman Demirel University Faculty of Medicine, Department of Dermatology
Havva Hilal Ayvaz Çelik Antalya Medstar Hospital Department of Dermatology
Fevziye Burcu Şirin Suleyman Demirel University Faculty of Medicine, Department of Biochemistry
Mehmet Bedir Suleyman Demirel University Faculty of Medicine, Department of Biochemistry
Hikmet Orhan Suleyman Demirel University Faculty of Medicine, Department of Biostatistics

Keywords:

E-FABP, Disease severity, Hidradenitis suppurativa, hs-CRP, Metabolic syndrome

Abstract

Introduction: Studies have shown that hidradenitis suppurativa (HS) is associated with obesity, dyslipidemia, hypertension, metabolic syndrome, and some autoinflammatory diseases. Studies on E-FABP, a member of the fatty acid binding protein family, suggest that this protein may be associated with psoriasis, obesity, metabolic syndrome, atherosclerosis, and autoimmune diseases.

Objectives: The aim of this study was to compare serum E-FABP levels in patients with HS and in healthy control subjects and to investigate the relationship between disease severity and metabolic parameters and serum E-FABP levels.

Methods: Forty-four HS patients and 45 healthy subjects were included in the study. In the patient and control groups, hs-CRP, routine biochemistry parameters, and serum lipid profiles were measured. Serum E-FABP levels were also determined by ELISA method. Blood pressure, pulse rate, and body measurements were also recorded in the patient and control groups. Obtained data were analyzed with SPSS 22.0.

Results: Serum E-FABP levels were found to be statistically significantly higher in the HS group than in healthy controls. However, no significant correlation was found between serum E-FABP levels and disease severity scores. The effect of E-FABP on the development of HS was determined by multivariate logistic regression analysis independent of age, sex, BMI, and hs-CRP. It was determined that the increase in E-FABP level increased the risk of HS development independently of other risk factors.

Conclusions: According to this study, E-FABP may be associated with the pathogenesis of HS rather than with disease severity or metabolic conditions.

References

Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa:a review of the literatür. Int J Womens Dermatol.2019;5(5):330-4. DOI: 10.1016/j.ijwd.2019.06.026. PMID: 31909152

Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023;41(3):471-479. DOI: 10.1016/j.det.2023.02.001. PMID: 37236715

Kaleta KP, Nikolakis G, Hossini AM et al. Metabolic Disorders/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach. Dermatology. 2022;238(2):251-259. DOI: 10.1159/000517017. PMID: 34293747

Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):50-61. DOI: 10.1111/jdv.16677. PMID: 32460374.

Ergun T. Hidradenitis suppurativa and the metabolic syndrome. Clin Dermatol. 2018 Jan-Feb;36(1):41-47. DOI: 10.1016/j.clindermatol.2017.09.007. PMID: 29241751.

Hung CT, Chiang CP, Chung CH et al. Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: A nationwide, population-based, cohort study in Taiwan. J Dermatol. 2019 Oct;46(10):867-873. DOI: 10.1111/1346-8138.15038. PMID: 31389066.

Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GB. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015 Nov;173(5):1142-55. DOI: 10.1111/bjd.14024. PMID: 26153913.

Zhang Y, Li B. E-FABP: regulator of immune function. Oncoscience. 2014 Jun 15;1(6):398-9. DOI: 10.18632/oncoscience.54. PMID: 25594037; PMCID: PMC4284618.

Kozłowska D, Myśliwiec H, Harasim-Symbor E, Milewska AJ, Chabowski A, Flisiak I. Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis. Mol Biol Rep. 2021 May;48(5):4421-4429. DOI: 10.1007/s11033-021-06461-3. PMID: 34131888; PMCID: PMC8260421.

Zhang Y, Li Q, Rao E, Sun Y et al. Epidermal Fatty Acid binding protein promotes skin inflammation induced by high-fat diet. Immunity. 2015 May 19;42(5):953-964. DOI: 10.1016/j.immuni.2015.04.016. PMID: 25992864.

Jin R, Hao J, Yi Y, Sauter E, Li B. Regulation of macrophage functions by FABP-mediated inflammatory and metabolic pathways. Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Aug;1866(8):158964. DOI: 10.1016/j.bbalip.2021.158964. PMID: 33984518; PMCID: PMC8169605.

Yeung DC, Wang Y, Xu A et al. Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur Heart J. 2008 Sep;29(17):2156-63. DOI: 10.1093/eurheartj/ehn295. PMID: 18603624.

Rao E, Singh P, Li Y et al. Targeting epidermal fatty acid binding protein for treatment of experimental autoimmune encephalomyelitis. BMC Immunol. 2015 May 12;16:28. DOI: 10.1186/s12865-015-0091-2. PMID: 25962726; PMCID: PMC4427938.14.

Dallaglio, K., Marconi, A., Truzzi, F et al. E‐FABP induces differentiation in normal human keratinocytes and modulates the differentiation process in psoriatic keratinocytes in vitro. Experimental dermatology, 2013 22(4), 255-261. DOI: 10.1111/exd.12111. PMID: 23528210

Goldburg, S. R., Strober, B. E., & Payette, M. J. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology, 2020 82(5), 1045-1058. DOI: 10.1016/j.jaad.2019.08.090. PMID: 31604104

Yamane Y, Moriyama K, Yasuda C et al. New horny layer marker proteins for evaluating skin condition in atopic dermatitis. Int Arch Allergy Immunol. 2009;150(1):89-101. DOI: 10.1159/000210385. PMID: 19339807.

Yin D, Hao J, Jin R et al. Epidermal Fatty Acid‒Binding Protein Mediates Depilatory-Induced Acute Skin Inflammation. J Invest Dermatol. 2022 Jul;142(7):1824-1834.e7. DOI: 10.1016/j.jid.2021.11.040. PMID: 34942197; PMCID: PMC9639752.

Malvaso, D., Calabrese, L., Chiricozzi, A et al. IL-17 inhibition: a valid therapeutic strategy in the management of hidradenitis suppurativa. Pharmaceutics, 2023 15(10), 2450. DOI: 10.3390/pharmaceutics15102450 PMID: 37896210 PMCID: PMC10609891

Owczarczyk-Saczonek A, Czerwiñska J, Orylska M, Placek W. Effect of methotrexate treatment on the expression of epidermal-fatty acid-binding protein (E-FABP) and apolipoproteins in patients with psoriasis. Postepy Dermatol Alergol. 2020 Jun;37(3):401-406. DOI: 10.5114/ada.2020.96109. PMID: 32792883; PMCID: PMC7394159.

Kuijpers AL, Bergers M, Siegenthaler G, Zeeuwen PL, van de Kerkhof PC, Schalkwijk J. Skin-derived antileukoproteinase (SKALP) and epidermal fatty acid-binding protein (E-FABP): two novel markers of the psoriatic phenotype that respond differentially to topical steroid. Acta Derm Venereol. 1997 Jan;77(1):14-9. DOI: 10.2340/0001555577014019. PMID: 9059669.

Miyake T, Ogawa E, Mikoshiba A et al. Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. J Dermatol Sci. 2012 Dec;68(3):199-202. DOI: 10.1016/j.jdermsci.2012.09.002. PMID: 23039948.

Bagheri R, Qasim AN, Mehta NN et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol. 2010 Oct 15;106(8):1118-23. DOI: 10.1016/j.amjcard.2010.06.028. PMID: 20920650; PMCID: PMC3108486.

Furuhashi M, Sakuma I, Morimoto T et al. Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne). 2020 Sep 23;11:575557. DOI: 10.3389/fendo.2020.575557. PMID: 33071982; PMCID: PMC7538548.

Hong J, Gu W, Zhang Y et al. Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chineseadults.Atherosclerosis.2011Jul;217(1):194200.DOI:10.1016/j.atherosclerosis.2011.03.002. PMID: 21492859.

Ibarretxe D, Girona J, Amigó N et al. Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders. J Clin Lipidol. 2016 Mar-Apr;10(2):330-8.e2. DOI: 10.1016/j.jacl.2015.12.012. PMID: 27055964.

Miller IM, Ring HC, Prens EP et al. Leukocyte Profile in Peripheral Blood and Neutrophil-Lymphocyte Ratio in Hidradenitis Suppurativa: A Comparative Cross-Sectional Study of 462 Cases. Dermatology. 2016;232(4):511-9. DOI: 10.1159/000446021. PMID: 27287331.